{"url_path":"/sec/nage/8-k/2026-06-29/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1386570/0001386570-26-000035-index.html","accession_number":"0001386570-26-000035","cik":"0001386570","ticker":"NAGE","issuer_name":"Niagen Bioscience, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1386570/0001386570-26-000035-index.html","primary_entity_key":"0001386570","primary_entity_name":"Niagen Bioscience, Inc."},"word_count":198,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nSet forth below are the results of the matters submitted for a vote of stockholders at the Company’s 2026 Annual Meeting.\n\nProposal 1 — Election of directors.\n\nThe following directors were elected to serve until the Company’s 2027 Annual Meeting of Stockholders and until his or her successor is elected, or, if sooner, until such director’s death, resignation or removal.\n\nDirector ElectedForWithheldBroker Non-Votes\n\nFrank L. Jaksch, Jr.44,531,507759,87013,274,979\n\nRobert Fried44,822,825468,55213,274,979\n\nSteven Rubin28,495,14716,796,23013,274,979\n\nWendy Yu44,520,972770,40513,274,979\n\nGary Ng44,446,052845,32513,274,979\n\nKristin Patrick43,608,0141,683,36313,274,979\n\nAnn Cohen44,360,218931,15913,274,979\n\nHamed Shahbazi30,544,08614,747,29113,274,979\n\nProposal 2 — Ratification of the appointment of Crowe LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.\n\nForAgainstAbstainBroker Non-Votes\n\n56,152,0662,256,090158,200—\n\n* No broker non-votes arose in connection with Proposal 2.\n\nProposal 3 — Approval, on an advisory basis, of the compensation paid to the Company’s named executive officers.\n\nForAgainstAbstainBroker Non-Votes\n\n43,188,9581,930,441171,97813,274,979\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nNIAGEN BIOSCIENCE, INC.\n\nDated: June 29, 2026By: /s/ Ozan Pamir\n\nName: Ozan Pamir\n\nChief Financial Officer"}